Printer Friendly

SYNOREX INCORPORATED ANNOUNCES ADVANCEMENTS IN DRUG-DELIVERY TECHNOLOGY AND BUSINESS

 SYNOREX INCORPORATED ANNOUNCES ADVANCEMENTS IN
 DRUG-DELIVERY TECHNOLOGY AND BUSINESS
 BURLINGTON, N.C., May 5 /PRNewswire/ -- Imagine, no more needles! No more pills every few hours! That's the goal of Synorex Incorporated, an early stage, pharmaceutical company formed to develop, manufacture and market advanced penetration enhancers for drug delivery systems. Thanks to research achievements by Dr. Raj, the founder, Synorex has the leading-edge technology for chemical enhancement of transdermal drug delivery. Most of us are familiar with the "patches" for smoking cessation and to prevent motion sickness. Now, a long list of pharmaceuticals can be delivered through the skin or mucous membrane, potentially benefiting millions of patients.
 Synorex is pleased to announce that to date five patents have been granted for advanced penetration enhancers that can be used in patches, creams, gels, and nasal sprays; as well as for ultrasonic and iontophoretic drug delivery systems. Three more patents are pending. One of these patents is believed by Dr. Raj to protect a completely novel, nonirritating, safe and highly effective penetration enhancer designated SR-38.
 We are also pleased to announce that the lawsuit that threatened Synorex's patents and technology since 1986 was favorably settled on Feb. 19, 1992. All key patents and applications are clearly the property of Synorex. The business advancement of Synorex can now proceed unhindered.
 In order to provide for that advancement, Synorex is pleased to announce the appointment of Dr. Arden A. Kelton as president and director, and Ron Robertson as CFO. Both have extensive experience as entrepreneurs. Other new board members will include James G. Watt, chairman, and David G. Schrunk, M.D. Both have experience as investors and directors of other hi-tech companies. The appointments for Vice President of Marketing & Sales and Chief Operating Officer are under consideration.
 Currently, Synorex is raising private investment, intends to seek venture capital investment, and plans to have an early initial public offering of stock. Temporary corporate offices are located in Burlington, N.C. Locations for an expanded and consolidated Synorex are under consideration in California, North Carolina, Colorado and Texas.
 -0- 5/5/92
 /CONTACT: Arden A. Kelton, President, or Ron Robertson, CFO, Synorex Incorporated, 919-538-0099/ CO: Synorex Incorporated ST: North Carolina IN: MTC SU: PDT


CM -- CH001 -- 6350 05/05/92 08:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:376
Previous Article:ALLOU HEALTH & BEAUTY CARE REPORTS RECORD PRELIMINARY YEAR-END RESULTS; REVENUES UP APPROXIMATELY 41 PERCENT, NET INCOME UP SHARPLY
Next Article:VIDEO INVESTMENT INSPECTION PROGRAM PROVIDES COST-EFFECTIVE CONSUMER PROTECTION WORLDWIDE


Related Articles
IMPRESSION DELIVERY CORPORATION ACQUIRES AIDS-TREATMENT TECHNOLOGY
DURA PHARAMACEUTICALS AND SRI INTERNATIONAL FORM STRATEGIC ALLIANCE
New Formulation of Anti-Incontinence Drug Marks First Commercial Availability of Penwest's TIMERx(R) Technology
RTP Pharma Inc. Announces US$3.5 Million Investment by EGS Partners and Credit Agricole
Atrix Awarded Two NIH Research Grants for Atrigel Delivery Technology.
Neurogen Reports Progress in Installing AIDD Technology at Pfizer Inc.
CIMA Announces New Vice President of Business Development and Vice President Of Quality Assurance.
Access Pharmaceuticals Announces the Filing of a Product License Application In the UK for Zindaclin(TM); UK Registration Possible in 2001.
Vyteris Inc. is Created as Becton Dickinson Divests Transdermal Drug Delivery Unit.
MicroCHIPS Names Tamborlane to New Scientific Advisory Board.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters